IC
RIGL icon

Ikarian Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Ikarian Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-70,277
Closed -$794K – 154
2022
Q2 		$794K Sell
70,277
-143,436
-67% -$2.88M 0.14% 86
2022
Q1 		$6.39M Buy
213,713
+169,777
+386% +$4.6M 0.84% 34
2021
Q4 		$1.16M Buy
+43,936
New +$1.33M 0.17% 93
2021
Q1 		– Sell
-34,553
Closed -$1.21M – 330
2020
Q4 		$1.21M Sell
34,553
-35,000
-50% -$1.01M 0.05% 172
2020
Q3 		$1.67M Sell
69,553
-98,500
-59% -$2.42M 0.12% 119
2020
Q2 		$3.08M Hold
168,053
– – 0.24% 91
2020
Q1 		$2.62M Buy
168,053
+133,053
+380% +$2.83M 0.2% 86
2019
Q4 		$749K Buy
+35,000
New +$721K 0.12% 85

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ikarian Capital's RIGL Position: Q3 2022 in Review

Ikarian Capital sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 70,277 shares — an estimated $794K sold.

Ikarian Capital first reported a position in RIGL in Q4 2019 and held it in 8 quarters. The position peaked at $6.39M in Q1 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

  • Ikarian Capital reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 70,277 Rigel Pharmaceuticals shares in Q3 2022, an estimated $794K.
  • Ikarian Capital first reported a position in Rigel Pharmaceuticals in Q4 2019 and held it in 8 quarters.
  • Ikarian Capital's Rigel Pharmaceuticals position peaked at $6.39M in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.